[go: up one dir, main page]

MX2021003094A - Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas. - Google Patents

Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.

Info

Publication number
MX2021003094A
MX2021003094A MX2021003094A MX2021003094A MX2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A
Authority
MX
Mexico
Prior art keywords
corticosteroid
compositions
methods
crac
crac inhibitor
Prior art date
Application number
MX2021003094A
Other languages
English (en)
Inventor
Srikant Viswanadha
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals A G filed Critical Rhizen Pharmaceuticals A G
Publication of MX2021003094A publication Critical patent/MX2021003094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a un método para tratar una enfermedad o afección autoinmunitaria, respiratoria y/o inflamatoria (tal como psoriasis, artritis reumatoide, asma o EPOC) mediante la administración de al menos un modulador de calcio activado por liberación de calcio (CRAC) (tal como un inhibidor de CRAC) y al menos un corticosteroide.
MX2021003094A 2018-09-14 2019-09-13 Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas. MX2021003094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841034710 2018-09-14
PCT/IB2019/057746 WO2020053834A1 (en) 2018-09-14 2019-09-13 Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021003094A true MX2021003094A (es) 2021-05-12

Family

ID=68242781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003094A MX2021003094A (es) 2018-09-14 2019-09-13 Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.

Country Status (15)

Country Link
US (1) US20220040162A1 (es)
EP (1) EP3849552A1 (es)
JP (1) JP2022508468A (es)
KR (1) KR20210062023A (es)
CN (1) CN113557020A (es)
AU (1) AU2019340601A1 (es)
BR (1) BR112021004893A2 (es)
CA (1) CA3112907A1 (es)
CL (1) CL2021000616A1 (es)
CO (1) CO2021004013A2 (es)
EA (1) EA202190556A1 (es)
IL (1) IL281342A (es)
MX (1) MX2021003094A (es)
SG (1) SG11202102491RA (es)
WO (1) WO2020053834A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189013A1 (en) * 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
EP1143013A1 (en) 2000-04-03 2001-10-10 Warner-Lambert Company Methods and compositions for screening Icrac modulators
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
US7645588B2 (en) 2003-03-04 2010-01-12 Calcimedica, Inc. Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
CA2533598C (en) 2003-07-23 2012-09-11 Synta Pharmaceuticals, Corp. Method for modulating calcium ion-release-activated calcium ion channels
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
JP2008518600A (ja) 2004-10-29 2008-06-05 ケミコン インターナショナル，インコーポレイテッド Ｇタンパク質共役型レセプターおよびそのリガンドをアッセイするための組成物および方法
AU2006211646B2 (en) 2005-01-07 2012-09-20 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
TWI444187B (zh) 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
AU2007208227A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
CA2640091A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
EP1984338B8 (en) 2006-01-31 2013-05-22 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
WO2007109362A2 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
US20080096227A1 (en) 2006-04-10 2008-04-24 Reinhold Penner CRAC modulators and use of same for drug discovery
US20080039392A1 (en) 2006-05-26 2008-02-14 The Regents Of The University Of California CRAC channel and modulator screening methods
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
WO2008063504A2 (en) 2006-11-13 2008-05-29 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
EP2129219A4 (en) 2007-02-16 2012-08-29 Synta Pharmaceuticals Corp SUBSTITUTED FUSED CYCLE COMPOUNDS USED IN CASES OF INFLAMMATION OR IMMUNE DISORDERS
NZ580195A (en) 2007-03-05 2012-03-30 Univ Queensland Targeting crac for breast cancer therapy and/or diagnosis
EP2135077B1 (en) 2007-03-23 2016-09-28 The Queen's Medical Center Assays and methods for determining stim2 activity
US8507269B2 (en) 2007-05-24 2013-08-13 Calcimedica, Inc. Calcium channel proteins and uses thereof
US8349841B2 (en) 2007-08-01 2013-01-08 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
CA2695148A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
US8435996B2 (en) 2007-08-01 2013-05-07 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8324219B2 (en) 2007-09-20 2012-12-04 Synta Pharmaceuticals Corp. Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2240029A4 (en) 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2010034011A2 (en) 2008-09-22 2010-03-25 Calcimedica, Inc. Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
WO2010034003A2 (en) 2008-09-22 2010-03-25 Calcimedica, Inc. Benzylthiotetrazole inhibitors of store operated calcium release
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010039236A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2009300317A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20100130522A1 (en) 2008-10-01 2010-05-27 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
US20110230536A1 (en) * 2008-10-24 2011-09-22 Calcimedica, Inc. Phenylpyrazole inhibitors of store operated calcium release
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
WO2011109551A2 (en) 2010-03-03 2011-09-09 Calcimedica Inc. Compounds that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
EP2619200A4 (en) 2010-09-22 2014-10-15 Calcimedica Inc COMPOUNDS AS MODULATORS OF INTRA CELLULAR CALCIUM
WO2012056478A1 (en) 2010-10-30 2012-05-03 Lupin Limited Oxazole and isoxazole crac modulators
WO2012079020A2 (en) 2010-12-09 2012-06-14 The Board Of Trustees Of The Leland Stanford Junior University Compounds that modulate store operated calcium channels
US20130143927A1 (en) 2011-06-10 2013-06-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013050270A1 (en) 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Benzoxazine derivatives as crac modulators
US20130090334A1 (en) 2011-10-05 2013-04-11 Hoffmann-La Roche Inc Azabenzoxazine derivatives as crac modulators
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059666A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20130158049A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013092444A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag Diazaindole inhibitors of crac
EP2844656A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyrazole compounds as crac modulators
IN2014MN02126A (es) 2012-05-02 2015-09-11 Lupin Ltd
WO2014043715A1 (en) 2012-09-17 2014-03-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20150103752A (ko) 2013-01-10 2015-09-11 그뤼넨탈 게엠베하 Crac 채널 억제제로서의 피라졸릴계 카복스아미드 ⅱ
HK1216300A1 (zh) 2013-01-10 2016-11-04 Grünenthal GmbH 作为crac通道抑制剂的基於吡唑基的甲醯胺i
AU2014282769A1 (en) 2013-06-21 2015-12-17 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
AU2014300629A1 (en) 2013-06-24 2015-12-24 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
EP2848615A1 (en) * 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
EP3033342A1 (en) 2013-08-13 2016-06-22 Grünenthal GmbH Annelated pyrroles and their use as crac inhibitors
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015090580A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides useful as calcium release activated calcium channel (icrac) inhibitors
WO2015197188A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
RS60450B1 (sr) * 2014-09-03 2020-07-31 Rhizen Pharmaceuticals Sa Postupak za tretiranje i kompozicije koje sadrže dvojni inhibitor pi3k delta-gama kinaze i kortikosteroid
US10213412B2 (en) 2015-01-13 2019-02-26 Vivreon Biosciences, Llc Modulators of CA2+ release-activated CA2+ (CRAC) channels and pharmaceutical uses thereof
ITUA20164199A1 (it) 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Modulatori di soce compisizioni e relativi usi
US20200253966A1 (en) 2017-01-26 2020-08-13 Calcimedica, Inc. Crac channel inhibitor compositions
WO2019082124A1 (en) * 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA

Also Published As

Publication number Publication date
US20220040162A1 (en) 2022-02-10
BR112021004893A2 (pt) 2021-06-01
WO2020053834A1 (en) 2020-03-19
JP2022508468A (ja) 2022-01-19
CA3112907A1 (en) 2020-03-19
CO2021004013A2 (es) 2021-07-19
KR20210062023A (ko) 2021-05-28
CL2021000616A1 (es) 2021-10-15
IL281342A (en) 2021-04-29
SG11202102491RA (en) 2021-04-29
CN113557020A (zh) 2021-10-26
AU2019340601A1 (en) 2021-05-13
EP3849552A1 (en) 2021-07-21
EA202190556A1 (ru) 2021-08-24

Similar Documents

Publication Publication Date Title
SA519402400B1 (ar) تركيبات وطرق لعلاج أمراض الهيموجلوبين
NZ754731A (en) Azolopyrimidine for the treatment of cancer-related disorders
PH12017500927A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
MX386086B (es) Composicion de cannabis
WO2018226622A8 (en) Compounds for treating huntington's disease
NZ734714A (en) Methods of purifying cannabinoids, compositions and kits thereof
PH12018501226A1 (en) Methods for treating huntingtons disease
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2021003094A (es) Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.
MX2017015132A (es) Hidrogel que porta inhibidor de hidrato.
MX2022006573A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
MX394167B (es) Polipeptidos enlazados a il-17a.
GB2558439A (en) Settable compositions with variable set times
MX2017003905A (es) Agente liquido anticontraccion para cemento.
EP3974451A3 (en) Methods of treating inflammatory diseases
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020005231A (es) Metodos de uso y composiciones que contienen dulaglutida.
MX2020009813A (es) Composiciones y metodos para tratar el prurito.
MX2020011472A (es) Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.
MX2022003834A (es) Materiales polimericos de ca?amo y metodos de fabricacion de los mismos.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.